The present invention relates to the use of bacteriophages to treat infections diseases. The invention provides a method for intermediate to large scale commercial production of bacteriophage composition, wherein the method reduces the production volume and elevates production yield. The invention further relates to improved bacteriophage compositions comprising specific sugars that reduce or abolish the bacterial phage-neutralizing activity.